StockVS

So-Young International Inc. (SY) 股票分析

医疗保健

So-Young International Inc.

$2.20

$-0.03 (-1.35%)

最后更新: 2026年5月26日

价格走势

分析

公司概述

So-Young International Inc. operates an online platform dedicated to delivering consumption healthcare services within the People's Republic of China, providing users with the So-Young Mobile App that grants access to medical aesthetic knowledge, community support, and reservation options for treatments with medical professionals. The company functions within the Healthcare sector, specifically under the Health Information Services industry, positioning itself as a digital intermediary connecting consumers with aesthetic medical services. With a market capitalization of $287.62M and annual revenue reaching $1.52B, the company demonstrates significant scale in the digital health landscape, though its employee count remains undisclosed. These valuation and revenue figures indicate that So-Young International Inc. has established a substantial presence in the Chinese market, leveraging its platform to generate substantial top-line growth despite facing profitability challenges in the current fiscal period.

财务健康

The company reported total revenue of $1.52B over the trailing twelve months, yet recorded a net income of -$242,300,992 and an EBITDA of -$220,548,992, revealing a substantial gap between top-line generation and bottom-line profitability that points to high operational costs or significant non-operating expenses. While the company holds substantial cash reserves of $871.68M, it maintains a debt load of $299.71M, resulting in a debt-to-equity ratio of 17.96, which suggests a highly leveraged balance sheet relative to its equity base. The gross margin stands at 47.8%, indicating that the company retains nearly half of its revenue after direct costs, while the operating margin of -22.4% and profit margin of -15.9% highlight the intense pressure on operating expenses and the inability to convert revenue into operating profit. The current ratio of 1.89 indicates that the company possesses 1.89 times the current assets necessary to cover its short-term liabilities, suggesting adequate short-term liquidity despite the negative earnings position. Return on Equity is recorded at -13.6% and Return on Assets at -6.2%, metrics that reveal management has yet to generate positive returns on its shareholders' capital or asset base. The absence of reported Free Cash Flow data limits the immediate assessment of cash generation capabilities, but the large cash balance relative to debt provides a buffer against the negative operating income.

估值评估

The valuation metrics present a complex picture, with a P/E Ratio (TTM) listed as N/A due to negative earnings and a Forward P/E of -11.76, which implies that the market is pricing in a significant turnaround or expects earnings to remain negative in the near term. The Price to Book ratio is 1.28, indicating that the market values the company at 28% above its tangible book value, a premium that investors may attribute to the growth potential of its digital platform and user base. The Price to Sales ratio of 0.19 and an EV/EBITDA of 1.07 suggest that the market is applying a multiple based on revenue rather than earnings, likely due to the current lack of profitability, while the low EV/EBITDA multiple reflects the company's negative earnings generation. The stock's 52-week trading range spans from a low of $0.67 to a high of $6.28, and without a specific current price provided in the data, the position within this range cannot be precisely calculated, though the wide spread suggests high volatility. The Beta value of 2.17 indicates that the stock's price volatility is more than twice that of the broader market, exposing investors to significant price swings that could amplify both gains and losses relative to a standard market index.

Growth & Income

Revenue growth for the company reached 24.8% year-over-year, demonstrating aggressive expansion in its top line, whereas Earnings Growth is listed as N/A due to the company's net loss, implying that revenue expansion has not yet translated into earnings improvement. The company does not pay dividends, as evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning that any generated cash or retained earnings are not distributed to shareholders but are instead reinvested into the business operations and platform development. This reinvestment strategy is typical for growth-stage companies in the healthcare technology sector that prioritize scaling their market share over returning capital to investors. The overall growth and income profile characterizes So-Young International Inc. as a high-volatility, non-dividend paying entity that relies entirely on future profitability to justify its current valuation and market cap.

同行比较

So-Young International Inc. (SY) 在健康信息服务行业运营。以下是其与市值最接近的同行的比较:

公司 代码 市值 市盈率
So-Young International Inc. SY $220.66M N/A
Veeva Systems Inc. VEEV $25.87B 29.1
BrightSpring Health Services, Inc. BTSG $11.70B 78.3
Tempus AI, Inc. TEM $8.38B N/A

健康信息服务行业平均市盈率为57.5倍。So-Young International Inc.的市盈率为N/A。

本分析由AI生成,仅供参考,不构成投资建议。数据可能存在延迟或不准确。在做出投资决策之前,请务必进行自己的研究并咨询合格的财务顾问。

关于So-Young International Inc.

So-Young International Inc. operates an online platform for consumption healthcare services in the People's Republic of China. The company offers So-Young Mobile App that offers users access to medical aesthetic knowledge, community support and reservation options for treatment with medical professionals, and medical aesthetic institutions; Weixin mini program to explore treatment options, check prices, schedule appointments, participate in online consultations, and track follow-ups; and medical aesthetic community content through its website soyoung.com. Its aesthetic centers offer non-invasive to minimally invasive procedures, including device-based options, such as thread lifts, intense pulsed light, ultrasound facelifts, picosecond lasers, and body contouring treatments, as well as injectable treatments, including skin boosters, hyaluronic acid-based products, botox, and type I and type III collagen. In addition, the company engages in the research and development, production, sale, and distribution of light therapy devices, including excimer laser systems, UV excimer therapy devices, LED and red-light therapy systems, and advanced laser and intense pulsed light technologies; surgical laser devices, including carbon dioxide laser machines, multi-wavelength and semiconductor laser systems for urological treatments, and hydrodynamic-assisted liposuction systems for plastic surgery, as well as pneumatic liquid spray devices skin cleansing. Further, it offers injectable products; sales and technical, maintenance, installation, operational training, error reporting, maintenance, and equipment packaging services; consumption healthcare services, including dermatology, dentistry and orthodontics, physical examinations, gynecology, and postnatal care; reservation services; and content management through beauty diaries, short-form videos, treatment reviews, featured articles, and chat messages. The company was founded in 2013 and is headquartered in Beijing, China.

公司简介以英文显示。

访问官网 →

关键指标

市值
$220.66M
市盈率
N/A
52周最高
$6.28
52周最低
$0.83
平均成交量
530.70K

数据由Yahoo Finance通过yfinance提供。每日更新。

公司信息

交易所
NASDAQ
国家
China
员工数
2,348